Unveiling the role of SYNGR4 in breast cancer development: a novel target for immunotherapy
Jie Ma, Hongtao Wang, Zhengwei Gui, Yuanrong Yang · 2025
Read Unveiling the role of SYNGR4 in breast cancer development: a novel target for immunotherapy by Jie Ma, Hongtao Wang, Zhengwei Gui, Yuanrong Yang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11788336.txt.
Description
Jie Ma and co-authors single out a little-studied protein, SYNGR4, as a possible new target in breast cancer. The gene is better known from nerve disease research, but database scans showed it runs high in many tumors, including breast tumors, and high levels track with worse outcomes for patients. Published in 2024, the study combined database analysis, patient samples from the authors' own center, cell experiments, and animal work.
Turning the protein up in breast cancer cells made them grow faster and move more. It also changed the tumor's immune neighborhood: support macrophages inside the tumor shifted toward the M2 type, which helps cancers rather than fighting them. Pathways tied to cell division ran hot alongside the protein. The authors argue this chain, from one protein to macrophage behavior, explains its effect on prognosis. They propose blocking or exploiting SYNGR4 as a fresh angle for breast cancer immunotherapy.
Catalog record
| CREATOR | Jie Ma, Hongtao Wang, Zhengwei Gui, Yuanrong Yang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |